Maze Therapeutics (MAZE) Change in Accured Expenses (2024 - 2026)

Maze Therapeutics has disclosed Change in Accured Expenses across 3 years of filings, most recently posting -$4.1 million for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$4.1 million, down 282.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $479000.0 (down 83.34% YoY), and the FY2025 annual result was $3.5 million, down 8.54% from the prior year.
• Change in Accured Expenses came in at -$4.1 million for Q1 2026 at Maze Therapeutics, down from $2.0 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $3.8 million in Q2 2024 to a low of -$4.1 million in Q1 2026.
• The 3-year median for Change in Accured Expenses is $106000.0 (2025), against an average of $358111.1.
• Peak annual rise in Change in Accured Expenses reached 245.31% in 2025, while the deepest fall reached 711.45% in 2025.
• Maze Therapeutics' Change in Accured Expenses stood at $1.8 million in 2024, then increased by 6.51% to $2.0 million in 2025, then tumbled by 307.13% to -$4.1 million in 2026.
• The last three Change in Accured Expenses figures came in at -$4.1 million (Q1 2026), $2.0 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.